By Regulatory Approvals — FDA approves Zimrixby (rituximab) and Garzulys (insulin aspart) biosimilars Generics and Biosimilars Initiative
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 2, 2026.